BioCentury
DATA GRAPHICS | Finance

Data Bytes: IPO queue remains hot

July 8, 2020 12:56 AM UTC

The IPO queue is getting longer by the day, now with 57 life sciences companies lined up to make public debuts on U.S. and Asian exchanges.

On Monday, antiviral play AlloVir Inc. became the latest to jump in line when it filed to raise up to $100 million in a NASDAQ IPO. Its lead allogeneic T cell therapy, Viralym-M. is slated to enter Phase III pivotal trials and Phase II proof-of-concept studies across several indications this year and next (see “AlloVir First to Test ElevateBio’s Model”). ...